How does this study impact clinical practice?

• Notably, after 16-week induction with lebrikizumab Q2W, both Q2W and Q4W dosing maintained improvement of AD signs and symptoms.
• The rate of rescue therapy was low, suggesting the effects were due to lebrikizumab, and not concomitant topical steroids.
• Loss of clinical response to lebrikizumab was slow, with around half of patients who were re-randomized to placebo still showing response at Week 52.
• The safety profile was consistent with previously published data.